Cytomedix‘s (OTC:CMXI) Aldagen acquisition signaled the company’s intention to establish a strong presence in regenerative medicine therapies and the deal fills needs for both companies. Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective [...]

Regenerative medicine company Cytomedix (OTC:CMXI) has acquired North Carolina stem cell technology company Aldagen in a stock deal valued at $40 million that broadens the firm’s regenerative therapies pipeline.Maryland-based Cytomedix develops biologically active regenerative therapies for wound care, inflammation and blood vessel development. The company has been diversifying to build its regenerative medicine capabilities. Aldagen’s [...]

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases.The trial showed that the company’s MultiStem technology may reduce the incidence and severity of graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem cell [...]

Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury.A $1.9 million grant to study traumatic brain injury (TBI) comes from the National Institute of Neurological Disorders and Stroke, according to a statement from [...]

Medical device firm Charter Medical has received European regulatory clearance for cryogenic stem cell containers.The CE Mark means that Charter’s cryogenic storage containers for hematopoietic stem cells, the stem cells that form blood and immune cells, can now be marketed in Europe. The containers are designed for cryogenic storage, preservation and transfer of these cells. [...]

Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients.At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures — a six-minute distance-walking test, as well as the Minnesota Living with Heart Failure [...]

Fresh off supplying the scaffold for the world’s second-ever artificial trachea implant, Ohio State University spinoff Nanofiber Solutions is hoping to expand its work with artificial organs.The Columbus, Ohio-based company’s technology could be used to create scaffolds for a number of other types of hollow organs, such as intestines, blood vessels and kidneys, chief technology [...]

Stem cell technology company Aldagen, which last year withdrew initial public stock offering plans that could have raised up to $80 million to finance R&D and clinical trials, is now raising money in much smaller increments.The Durham, North Carolina company is trying to raise $645,004, according to an amended securities filing — $120,000 more than [...]

Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack.The patent provides protection for “multiple techniques” for delivering the stem cells to treat the conditions, which also include congestive heart failure and myocardial ischemia, according to a statement from [...]

A two-year-old Ohio State University spinoff’s nanofiber scaffold was used to grow a patient’s own stem cells and then implanted into the patient after his trachea was removed — in an operation that’s being billed as the world’s second successful synthetic trachea transplant.Columbus-based Nanofiber Solutions designed and built the scaffold used in the procedure. The [...]